^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | modafinil (α1 adrenergic receptor agonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Network based analysis identifies TP53m-BRCA1/2wt-homologous recombination proficient (HRP) population with enhanced susceptibility to Vigil immunotherapy
Published date:
11/16/2021
Excerpt:
Phase IIb double-blind randomized placebo-controlled trial (NCT02346747) comparing Vigil and placebo in Stage III/IV resectable ovarian cancer....Improved relapse free survival in Vigil treated patients was found for the TP53m-BRCAwt-HRP group compared to placebo (21.1 months versus 5.6 months p = 0.0013).
DOI:
https://doi.org/10.1038/s41417-021-00400-x